Paper Dated: December 21, 2010

In Reply to USPTO Correspondence of June 21, 2010

Attorney Docket No. 0470-061930

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-17 (Cancelled).

Claim 18 (Currently Amended): A composition for stimulating appetite in humans a human comprising in a daily dosage form 14—1000 mg-pantothenic acid or an equivalent thereof of pantothenic acid selected from the group consisting of a salt, an ester or an ether of pantothenic acid, pantothenol; (R)-pantoate or a salt or an ester thereof, pantetheine or an ester or an ether thereof and coenzyme A, wherein the daily dosage form of pantothenic acid is 14 to 1000 mg of pantothenic acid, and wherein the daily dosage form of the equivalent of pantothenic acid is which equivalent comprises an equimolar amount of at least 14 to 1000 mg of pantothenic acid; and further comprising at least 15 En% proteins (or hydrolysed proteins or amino acids) that comprise 1.8 to 6 g of methionine per 100 g of the proteins, 5.8 to 12.0 g of lysine per 100 g of the proteins, 1.5 to 4.0 g of tryptophan per 100 g of the proteins and at least 8 g of leucine per 100 g of the proteins, and optionally and/or at least 32 En% to 40 En%-carbohydrates and/or at least 18 En% to 25 En%-lipids; wherein said composition having a caloric value of at least 100 kcal to about 1200 kcal-per daily dosage form.

Claim 19 (Currently Amended): The composition according to claim 18, wherein the proteins are selected from the group consisting of plantsplant proteins, vegetables vegetable proteins, eereals cereal proteins, seeds seed proteins and whey proteins.

Claim 20 (Currently Amended): The composition according to claim 19, wherein the whey proteins is acidic whey proteins.

Claim 21 (Cancelled).

Claim 22 (Currently Amended): The composition according to claim 18, wherein the proteins comprise further comprising serine and glycine in a serine/glycine ratio of 3.4 or higher.

Paper Dated: December 21, 2010

In Reply to USPTO Correspondence of June 21, 2010

Attorney Docket No. 0470-061930

Claim 23 (Currently Amended): The composition according to claim 18, further comprising per daily dosage form dose at least one component selected from the group consisting of 0.2-5-0.2 to 5 g of cysteine or one or more cysteine equivalents selected from the group consisting of cysteamine, L-cystine, L-cystine dimmer and N-acetyl cysteine, 0.2-5 g nucleotide or one or more nucleotide equivalents (1-10 g yeast, cytidine, uridine, nucleosides), 0.1-5 g beta alanine when the pantothenic acid is (R) pantoate, 300-3000 mg folic acid or one or more folic acid equivalents, 0.5-50 mg vitamin B6 or one or more vitamin B6 equivalents and 0.5 g of at least one choline source selected from the group consisting of choline, betaine, dimethylglycine and sarcosine.

Claim 24 (Currently Amended): The composition according to claim 18, wherein said composition has a the caloric value of is at least 600 kcal per daily dosage form.

Claim 25 (Currently Amended): The composition according to claim 18, wherein said composition has a the caloric value of is at least 900 kcal per daily dosage form.

Claim 26 (Currently Amended): The composition according to claim 18, wherein said composition has a the caloric value of is a least 1200 kcal per daily dosage form.

Claim 27 (Currently Amended): The composition according to claim 18, further comprising wherein the composition comprises the lipids in an amount of at least 1.5 g per 100 g composition.

Claim 28 (Currently Amended): The composition according to claim 18, further comprising wherein the composition comprises the lipids in an amount of at least 2.0 to 10 g per 100 g composition.

Claim 29 (Currently Amended): The composition according to claim 18, further comprising—wherein the composition comprises the lipids in an amount of at least 2.7 to 8 g per 100 g composition.

Claim 30 (Currently Amended): The composition according to claim 27, wherein the amount of lipids comprises at least 12 g saturated fatty acids per 100 g lipids.

Paper Dated: December 21, 2010

In Reply to USPTO Correspondence of June 21, 2010

Attorney Docket No. 0470-061930

Claim 31 (Currently Amended): The composition according to claim 27, wherein the amount of lipids comprises comprise at least 14 to 50 saturated fatty acids per 100 g lipids.

Claim 32 (Currently Amended): The composition according to claim 27, wherein the amount of lipids comprises comprise at least 4.0 g myristic acid per 100 g fatty acids the lipids.

Claim 33 (Previously Presented): The composition according to claim 18, wherein said composition has at least 25 En% lipids and at least 40 En% carbohydrates.

Claim 34 (Withdrawn): A method for stimulating appetite in a human, comprising manufacturing a composition comprising proteins (or hydrolysed proteins or amino acids) and pantothenic acid or an equivalent thereof, wherein said composition comprises at least 15 En% proteins (or hydrolysed proteins or amino acids) in a daily dosage of about 14 to 1000 mg pantothenic acid or an equivalent thereof, which equivalent comprises an equimolar amount of about 14 to 1000 mg pantothenic acid, and administering said composition to the human.

Claim 35 (Withdrawn): The method according to claim 34, wherein said method comprises the stabilisation and/or increase of body weight in the human.

Claim 36 (Withdrawn): The method according to claim 34, wherein said pantothenic acid or an equivalent thereof is selected from the group consisting of pantothenol, (R)-pantoate or salts or esters thereof, pantothenic acid or salts or esters or ethers thereof, pantetheine or esters or ethers thereof and coenzyme A.

Claim 37 (Withdrawn): The method according to claim 34, wherein said pantothenic acid or an equivalent thereof is selected from the group consisting of pantothenol, (R)-pantoate or salts or esters thereof and pantetheine or esters or salts thereof.

Claim 38 (Withdrawn): The method according to claim 34, wherein said method treats patients suffering from infections, serious liver, kidney or heart disease, cancer of any kind, intestinal obstruction, inflammatory bowel disease, pancreatitis, irritable bowl syndrome, appendicitis, endocrine problems, diabetes, hypothyroidism, autoimmune diseases or disorders, psychological

Paper Dated: December 21, 2010

In Reply to USPTO Correspondence of June 21, 2010

Attorney Docket No. 0470-061930

conditions, eating disorders, negative effects of medications or drugs, chemotherapy medications, alcohol, narcotics, antibiotics, diabetes medication, dementia, lung diseases, lung emphysema, traumata following surgery.

Claim 39 (Withdrawn): The method according to claim 34, wherein said method treats nausea during pregnancy.

Claim 40 (New): The composition according to claim 18, further comprising per daily dose at least one component selected from the group consisting of 0.2 to 5 g nucleotide or one or more nucleotide equivalents selected from the group consisting of cytidine, uridine and nucleosides; 300 to3000 mg folic acid or one or more folic acid equivalents selected from the group consisting of monoglutamate, poly-glutamate 5-methyl-folate, 10-methyl-folate, 5,10-methylene-folate, 5 formyl-folate and 10-formyl-folate; 0.5 to 50 mg vitamin B6 or one or more vitamin B6 equivalents selected from the group consisting of pyridoxine, pyridoxal and pyridoxamine; and 0.5 g of at least one choline source selected from the group consisting of choline, betaine, dimethylglycine and sarcosine.

Claim 41 (New): The composition according to claim 18, further comprising per daily dose 0.1 to 5 g beta-alanine when the composition comprises the pantothenic acid equivalent (R)-pantoate.